In summary, the activation of caspase-3/GSDME-dependent pyroptosis by nanostructured toxins targeting CXCR4 opens a novel and virtually unexplored therapeutic approach for HNSCC or other cancer types. The gene discussed is GSDME; the disease is cancer.